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Abstract The antibacterial activity of Lactobacillus casei
IMV B-7280, Lact. acidophilus IMV B-7279, Biﬁdobac-
terium longum VK1, and B. biﬁdum VK2 strains or their
various compositions in relation to Staphylococcus aureus
in vitro and on models of experimental intravaginal
staphylococcosis of mice was determined. It was found that
under the inﬂuence of these strains and their various
compositions, the in vitro growth of Staph. aureus was
inhibited, and the number of colonies of Staph. aureus
plated from the vagina of infected mice was signiﬁcantly
reduced. The antibacterial activity of these strains sepa-
rately and in compositions correlated with their ability to
improve the performance of the immune response. These
strains were the most effective in the following composi-
tions: Lact. casei IMV B-7280—B. longum VK1—
B. biﬁdum VK2. Strains of Lact. casei IMV B-7280, Lact.
acidophilus IMV B-7279, B. biﬁdum VK2, and B. longum
VK1 are prospective components of future probiotic drugs
efﬁcient in treating staphylococcosis and for immunity
correction.
Keywords Lactobacillus  Biﬁdobacterium 
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Introduction
Dysfunction of the immune system that emerges as the
result of changes in microbial ecology, widespread use of
modern chemopreparations of various natures, disruption
of the normal microbiota, etc., is one of the major causes of
increasingly hostile opportunistic commensal pathogens,
with subsequent development of infectious diseases of the
urogenital tract, including the anogenital area. The normal
biota of the vagina mainly consists of lactobacilli and a
smaller number of biﬁdobacteria, staphylococci, strepto-
cocci, coryneforms, enterococci, enterobacteria, etc. [19].
The vaginal microﬂora is now more frequently viewed as
an ‘‘ecosystem’’ [18]. The vaginal lactic acid bacteria
colonize the mucous membranes, maintain the proper
acidity (pH 4.3–4.7), control pathogens that cause urinary
tract infections and/or sexually transmitted diseases and
may also affect the development of the immune response to
causative agents of infectious diseases [18, 19]. Therefore,
disruption of the normal vaginal microﬂora, especially due
to reduction in the number or activity of lactobacilli [30],
frequently causes activation of aggressive forms of
opportunistic commensal pathogens, resulting in the
development of vaginosis or uncomplicated urinary tract
infections, as well as the emergence of other pathological
conditions.
It is known that uncomplicated infections of urinary
tract and vaginosis are often caused by opportunistic
commensal bacteria of the Staphylococcus genus [5, 15].
Staphylococcosis usually develops in people with reduced
nonspeciﬁc immunological resistance, as well as in people
who received large doses of immune suppressants, antibi-
otics, hormones, X-rays, etc. The latter has led to emer-
gence of resistant staphylococci. Frequent regressive
uncomplicated urinary tract infection can cause serious
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lasting bacterial vaginosis caused by staphylococci is
associated with a high risk of development of sexually
transmitted infectious diseases, which may increase the risk
of late miscarriage [7, 14, 26].
Therefore, developing alternative nature-derived treat-
ment(s) for patients with uncomplicated urinary tract
infections and vaginosis is of the utmost concern. This
treatment may include healthy vaginal lactic acid bacteria
with expressed antibacterial and immune modulatory
properties. There are only a few known strains of lacto-
bacilli that demonstrated a therapeutic effect in cases of
urogenital infectious diseases on experimental models and
in patients’ treatment [8].
We have previously characterized the following strains
of lactobacilli and biﬁdobacteria: Lactobacillus casei IMV
B-7280, Lact. acidophilus IMV B-7279, Biﬁdobacterium
longum VK1, and B. biﬁdum VK2. It was found that these
strains had in vitro antagonistic effects in relation to a wide
range of pathogenic and opportunistic microorganisms,
including causative agents of infectious diseases of the
urogenital tract. Furthermore, on the model of intact mice,
it was shown that in vivo they effectively induced pro-
duction of endogenous interferon and activated cells of the
phagocytic system, without affecting the production of the
pro-inﬂammatory cytokine tumor necrosis factor-a [27].
The aim of this study was to investigate the anti-
staphylococcal activity of the Lact. casei IMV B-7280,
Lact. acidophilus IMV B-7279, B. longum VK1 and
B. biﬁdum VK2 strains and their compositions on the model
of experimental intravaginal staphylococcosis of mice, and
determine their inﬂuence on innate immunity indicators.
Materials and Methods
Strains
Lact. casei IMV B-7280, Lact. acidophilus IMV B-7279,
B. longum VK1 and B. biﬁdum VK2 strains were used both
individually and in various compositions. These strains
were previously selected by us from associated cultures in
the course of laboratory study of fermented biological
materials. The study was performed using bacteria lyoph-
ilized in Cuddon Freeze Dryer FD1500 (New Zealand).
Before each experiment, the viability of the probiotic cul-
tures was tested by monitoring their growth on the Man-
Rogosa-Sharpe (MRS) agar medium at 37  C for 24–48 h.
Staph. aureus 8325-4 (kindly provided to us by Pro-
fessor V. S. Zuyeva, N. F. Gamaleya Institute of Epide-
miology and Microbiology, Russian Federation) had
plasmid-based resistance to gentamicin, allowing it to be
separated from other strains of vaginal staphylococcus
obtained from the environment through the use of selective
media containing this antibiotic.
Staph. aureus 8325-4 was grown on selective medium
for staphylococci (BAIRD-PARKER-Agar, Merck, Ger-
many) containing gentamicin (15 lg/ml) at 37  C for 24 h.
In Vitro Antagonistic Activity Assays
The antagonistic activity of Lact. casei IMV B-7280, Lact.
acidophilus IMV B-7279, B. longum VK1 and B. biﬁdum
VK2 strains was determined in vitro in relation to the
laboratory collection strains Staph. aureus 209-P, Staph.
aureus 43 and Staph. aureus 8325-4 (D. K. Zabolotny
Institute of Microbiology and Virology of the National
Academy of Sciences of Ukraine).
In the study of antagonistic activity of probiotic cultures,
the method of perpendicular strokes on the MRS medium
[20] was used. Test cultures of lactobacillus or biﬁdobac-
teria strains were collected after 24 h of cultivation. The
degree of sensitivity of the test cultures was evaluated
according to the size of the zones of growth inhibition:
5–15 mm—low-sensitive, 15–20 mm—moderately sensi-
tive, 30–40 mm—highly sensitive.
Model of Staphylococcal Intravaginal Infection
and Treatment of Mice with Lactobacilli and/
or Biﬁdobacteria
Experimental studies were performed on six-week-old
female BALB/c mice, synchronized in their estral cycle.
All studies were performed taking into account the rules of
the European Convention for the protection of vertebrate
animals. Staphylococcosis was modeled through intrava-
ginal administration of the Staph. aureus 8325-4 daily
culture to mice, in doses of 5 9 10
7 cells per animal. The
following clinical manifestations of the infection process
were observed in the infected mice: signiﬁcant increase in
whitish mucous secretions of the vagina, elevation of body
temperature, inactivity, and loss of appetite.
Twenty-four hours after infection, mice were given an
intravaginal injection of a suspension of lyophilized lac-
tobacillus and/or biﬁdobacteria cells in saline solution at a
dose of 1 9 10
6 cells per animal, once per day for 7 days.
Strains were injected individually and in the following
combinations: Lact. casei IMV B-7280—Lact. acidophilus
IMV B-7279; Lact. casei IMV B-7280—B. longum VK1;
Lact. casei IMV B-7280—B. biﬁdum VK2; Lact. aci-
dophilus IMV B-7279—B. longum VK1; Lact. acidophilus
IMV B-7279—B. biﬁdum VK2; Lact. casei IMV B-7280—
B. longum VK1—B. biﬁdum VK2; Lact. casei IMV
B-7280—B. longum VK1—Lact. acidophilus IMV
B-7279; Lact. acidophilus—B. longum VK1—B. biﬁdum
VK2; Lact. casei IMV B-7280—B. biﬁdum VK2—Lact.
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B. biﬁdum VK2—B. longum VK1—Lact. acidophilus IMV
B-7279 in equal proportion. A separate group was formed
by the infected mice that did not receive these strains or
their combinations, but received the saline intravaginally.
The control group included intact mice.
Quantiﬁcation of the Antibacterial Activity In Vivo
On the ﬁrst, third, sixth, ninth and twelfth day after the
injection of the lactobacillus and/or biﬁdobacteria strains,
alone or in various combinations, into the mice, Staph.
aureus 8325-4 was collected from the vagina and plated
onto a selective medium for staphylococci containing
gentamicin. The material was collected using standardized
sterile cotton tampons. Swabs from each tampon were
performed with 1 ml of saline. After cultivation at 37  C
for 24 h, the number of colony forming units was counted,
given that one such colony corresponds to one bacterium.
Determining the Number of T- and B-Lymphocytes
in the Spleen
On the ﬁrst, third, sixth and ninth day after the injection of
the lactobacillus and/or biﬁdobacteria strains, alone or in
combinations, into the mice, the spleens were extracted
from the killed mice, and suspensions of splenocytes were
prepared in RPMI-1640 culture medium. Leukocytes were
extracted from the spleen cell suspension by fractionating
cells in ﬁcoll-verohraﬁn density gradient (q = 1.077 g/cm
3)
by centrifuging (on the centrifuge/vortex Multi-Spin
MSC-3000) at 400g for 15 min. The cells were then washed
twice in the RPMI-1640 culture medium by centrifuging at
400g for 10 min. Surface antigens of T- and B-lymphocytes
were investigated with the help of the direct immunoﬂuo-
rescence method. Monoclonal antibodies to CD3?, CD4?,
CD8? and CD19? antigens (MACS, Miltenyi Biotec,
Germany) were used in the work. Calculation of T- and
B-lymphocytes and analysis of the results were performed
on a FACStar Plus cytoﬂuorometer (Becton–Dickinson,
USA).
Statistics
All digital data received were processed with the help of
the Origin Pro 8.5. software through analysis of variance.
Numerical data were represented as arithmetic average and
standard error (M ± m). The null hypothesis for the con-
trol and experimental comparative groups was checked
using Wilcoxon–Mann–Whitney (U) and Kolmogorov–
Smirnov nonparametric criteria. The differences between
the groups were considered statistically meaningful at
P\0.05.
Results
Antagonistic Action of Lactobacilli and Biﬁdobacteria
in Relation to Staph. aureus
It was shown that all the tested probiotic cultures possess
antagonistic activity in vitro in relation to the laboratory
strains of Staph. aureus, including Staph. aureus 8325-4
(Table 1). Zones of growth inhibition of the laboratory test
cultures varied for the Lact. acidophilus IMV B-7279 strain
within 14–35 mm, for Lact. casei IMV B-7280 within
11–42 mm, for B. biﬁdum VK-1 within 17–39 mm, and for
B. longum VK-2 within 5–20 mm. The growth of some test
cultures was inhibited almost completely. Thus, Lact.
acidophilus IMV B-7279 almost completely prevented the
growth of Staph. aureus 8325-4 and other Staph. aureus
spp., while Lact. casei IMV B-7280 prevented the growth
of Staph. aureus spp. B. biﬁdum VK-1 also caused rela-
tively large zones of growth inhibition when tested against
Staph. aureus 43 and other Staph. aureus spp.
Lact. acidophilus IMV B-7279 and B. biﬁdum VK-1 had
the most effective antagonistic action in relation to Staph.
aureus 8325-4 in vitro, while Lact. casei IMV B-7280 and
B. longum VK-2 were the least effective. Thus, S. aureus
8325-4 was highly sensitive to Lact. acidophilus IMV
B-7279, moderately sensitive to B. biﬁdum VK-1 and low-
sensitive to Lact. casei IMV B-7280 and B. longum VK-2.
Table 1 Antagonistic activity of Lact. casei IMV B-7280, Lact. acidophilus IMV B-7279, B. longum VK1, and B. biﬁdum VK2 in relation to
S. aureus in vitro
Test-culture Area of growth retardation, mm
Lact. acidophilus IMV B-7279 Lact. casei IMV B-7280 B. biﬁdum VK-1 B. longum VK-2
Staph. aureus 209-P 22.0 ± 1.3 16.0 ± 0.9 17.0 ± 1.1 16.0 ± 1.0
Staph. aureus 43 14.0 ± 2.1 21.0 ± 1.7 31.0 ± 1.2 5.0 ± 0.8
Staph. aureus 8325-4 36.0 ± 1.9 11.0 ± 0.8 24.0 ± 2.1 11.0 ± 2.4
Staph. aureus spp. 34.0 ± 2.0 42.0 ± 1.3 39.0 ± 1.5 20.0 ± 1.2
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123The following data were obtained from the study of the
anti-staphylococcal activity of the probiotic strains in vivo.
It was found that Staph. aureus 8325-4 was recovered from
the vagina of infected mice who did not receive probiotic
cultures or their compositions during the entire period of
observation (days 1–12) (Fig. 1). At the same time, after
injection of probiotic cultures in monocultures or in various
compositions into the infected mice, the number of colo-
nies of Staph. aureus 8325-4 decreased signiﬁcantly com-
pared to the infected mice that did not receive these strains
or their compositions. Thus, after injection of Lact. aci-
dophilus IMV B-7279, Lact. casei IMV B-7280, B. longum
VK1 or B. biﬁdum VK2 separately to mice, a decrease in
the number of Staph. aureus 8325-4 colonies, which was
recovered from the vagina, was observed from the ﬁrst day
and throughout the entire subsequent period of observation.
However, if we compare these probiotic cultures on an
individual basis (Fig. 1), on the ﬁrst and third days the
anti-staphylococcal activity of Lact. casei IMV B-7280,
B. longum VK1 and B. biﬁdum VK2 was higher than of
Lact. acidophilus IMV B-7279 (P\0.05). On the sixth
and ninth days Staph. aureus 8325-4 was recovered in the
smallest amount from the vagina of the infected mice who
received B. biﬁdum VK2 (P\0.05). On the twelfth day,
Staph. aureus 8325-4 was eliminated completely from
the vagina after injection of Lact. casei IMV B-7280,
B. biﬁdum VK2 or Lact. acidophilus IMV B-7279 into the
infected mice, but was still recovered in small amounts
from the vagina of the infected mice who received
B. longum VK1. These data show that the efﬁciency of
anti-staphylococcal actions of certain probiotic cultures in
vivo can be assessed as follows: B. biﬁdum VK2[Lact.
casei IMV B-7280[B. longum VK1/Lact. acidophilus
IMV B-7279.
The use of various compositions of probiotic cultures
was also accompanied by a signiﬁcant acceleration of the
process of elimination of staphylococcus from the vagina.
Comparing the anti-staphylococcal action of the composi-
tions of two probiotic cultures (Fig. 2) in vivo, the com-
bination of Lact. casei IMV B-7280 and B. longum VK1
(P\0.05) had the most effective action within the entire
period of observation. A rather high anti-staphylococcal
effect was demonstrated by the Lact. casei IMV B-7280—
B. biﬁdum VK2 composition (on the third, sixth, ninth, and
twelfth days). After injection of Lact. casei IMV B-7280—
B. longum VK1 or Lact. casei IMV B-7280—B. biﬁdum
VK2 compositions into the infected mice, staphylococcus
was completely eliminated from the vagina by the twelfth
day. Compared with these two compositions of probiotic
bacteria, the Lact. acidophilus IMV B-7279—B. biﬁdum
VK2 composition proved to be less effective (P\0.05).
The Lact. acidophilus IMV B-7279—B. longum VK1 (on
the sixth, ninth, and twelfth days; P\0.05) and Lact. casei
IMV B-7280—Lact. acidophilus IMV B-7279 (on the ﬁrst,
third, and sixth days; P\0.05) compositions had even
lower anti-staphylococcal activity compared with other
compositions of the two strains. After injecting the Lact.
acidophilus IMV B-7279—B. biﬁdum VK2, Lact. aci-
dophilus IMV B-7279—B. longum VK1, or Lact. casei
IMV B-7280—Lact. acidophilus IMV B-7279 composi-
tions separately into the mice, staphylococcus was recov-
ered from the vagina on the twelfth day, but at a much
smaller amount than that from the infected mice who did
not receive compositions of probiotic cultures. It is worth
noting that, contrary to other compositions of the two
strains, it was the Lact. casei IMV B-7280—B. longum
VK1 composition that was a more active antagonist of
Fig. 1 Number of colonies of Staph. aureus 8325-4, which was
sowed from the vagina of the infected mice after receiving
intravaginal injection of probiotic strains of lactobacilli and biﬁdo-
bacteria, each of them separately
Fig. 2 Number of colonies of Staph. aureus 8325-4, which was
sowed from the vagina of the infected mice after receiving
intravaginal injection of compositions of two probiotic strains of
lactobacilli and biﬁdobacteria, each of them separately
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123staphylococcus during the entire period of observation than
Lact. casei IMV B-7280 or B. longum VK1 separately.
As shown in Fig. 3, among the compositions of the three
strains of probiotic cultures, Lact. casei IMV B-7280—
B. longum VK1—B. biﬁdum VK2 and Lact. casei IMV
B-7280—B. biﬁdum VK2—Lact. acidophilus IMV B-7279
had the best anti-staphylococcal action on the ﬁrst, third,
and sixth days, compared with other compositions of three
and four strains of bacteria (P\0.05). The efﬁciency of
the Lact. casei IMV B-7280—B. longum VK1—Lact.
acidophilus IMV B-7279 composition appeared to be the
same on the third day as that of the two previously men-
tioned triple compositions, but the activity was less on the
ﬁrst and sixth days (P\0.05). The lowest anti-staphylo-
coccal activity on the ﬁrst, third, and sixth days was
demonstrated by the Lact. acidophilus—B. longum VK1—
B. biﬁdum VK2 (P\0.05) and Lact. casei IMV B-7280—
B. biﬁdum VK2—B. longum VK1—Lact. acidophilus IMV
B-7279 (P\0.05) compositions, compared to other com-
positions of three strains. On the ninth and twelfth days,
Staph. aureus 8325-4 was not recovered from the vagina of
the infected mice who received the Lact. casei IMV
B-7280—B. longum VK1—B. biﬁdum VK2 or Lact. casei
IMV B-7280—B. longum VK1—Lact. acidophilus IMV
B-7279 compositions. After injection of the Lact. aci-
dophilus—B. longum VK1—B. biﬁdum VK2, Lact. casei
IMV B-7280—B. biﬁdum VK2—Lact. acidophilus IMV
B-7279, or Lact. casei IMV B-7280—B. biﬁdum VK2—
B. longum VK1—Lact. acidophilus IMV B-7279 compo-
sitions to the mice, Staph. aureus 8325-4 was recovered
from the vagina of the infected mice on the ninth day.
From the vagina of the mice who received the composition
of the four strains (Lact. casei IMV B-7280—B. biﬁdum
VK2—B. longum VK1—Lact. acidophilus IMV B-7279),
Staph. aureus 8325-4 was also recovered on the twelfth day.
Analyzing the data obtained, it is possible to conclude
that the Lact. casei IMV B-7280—B. longum VK1—
B. biﬁdum VK2 composition appeared to be the biggest
antagonist of Staph. aureus 8325-4. The anti-staphylococ-
cal activity of the Lact. casei IMV B-7280—B. longum
VK1—B. biﬁdum VK2 composition on the ﬁrst day after
injection into the mice was the same as after injecting these
monocultures separately. However, on the third, sixth, and
ninth days, the anti-staphylococcal activity of this com-
position appeared to be better than that of the monocultures
injected separately. On the twelfth day, Staph. aureus
8325-4 was still recovered out from the vagina of infected
mice who received B. longum VK1 separately. On the ﬁrst
day, the efﬁciency of the Lact. casei IMV B-7280—
B. longum VK1—B. biﬁdum VK2 composition was lower
than that of the Lact. casei IMV B-7280—B. longum VK1
and Lact. casei IMV B-7280—B. biﬁdum VK2 composi-
tions, but on the third and sixth days it was the same as that
of the compositions of two strains. At the same time, on the
ninth day, staphylococcus was fully eliminated from the
vagina of the mice that received the Lact. casei IMV
B-7280—B. longum VK1—B. biﬁdum VK2 composition,
but was still recovered after the injection of the Lact. casei
IMV B-7280—B. longum VK1 or Lact. casei IMV
B-7280—B. biﬁdum VK2 compositions into the mice.
Thus, comparing the strains separately and in various
compositions with each other, it was determined that the
Lact. casei IMV B-7280—B. longum VK1—B. biﬁdum
VK2 composition is the most promising combination for
the creation of a probiotic drug with anti-staphylococcal
activity.
Immune-Modulating Effect of the Lactobacilli
and Biﬁdobacteria Strains
Cellular and humoral immunity are activated in the course
of development of the immune response of an organism
against staphylococci, because in the pathogenesis of dis-
eases caused by staphylococcus, a certain role is played by
both bacterial cells and their exotoxins. Therefore, the
study of the number of CD3? T-lymphocytes and their
speciﬁc subpopulations (CD4? T-helper cells, CD8?
T-suppressors), and CD19? B-lymphocytes in the spleen
of mice partly allows us to assess whether the strains of
lactobacilli and biﬁdobacteria inﬂuenced the development
of a systemic immune response in cases of intravaginal
staphylococcosis. It was shown that the number of CD3?,
CD4?, CD8?, and CD19? cells, as well as the CD4/CD8
index, changed in cases of intravaginal staphylococcal
infection (Table 2). After infection of the mice with
staphylococcus on the third day, a reduction in the number
Fig. 3 Number of colonies of Staph. aureus 8325-4, which was
sowed from the vagina of the infected mice after receiving
intravaginal injection of compositions of three or four probiotic
strains of lactobacilli and biﬁdobacteria, each of them separately
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123of CD3? and CD4? cells in the spleen was observed,
while the level of CD8? cells was normal, compared to the
control level (intact mice), demonstrating the development
of a systemic immune response to staphylococcus. By
reducing the number of CD4? cells on the third day, a
decrease in the CD4/CD8 index was observed in the
infected mice. At the other times of observation (ﬁrst,
sixth, and ninth days), the number of these cells and the
CD4/CD8 index were preserved at the control level. The
number of CD19? cells in the spleens of the infected mice
did not change on the ﬁrst and third days, increased more
than twice (P\0.05) on the sixth day, and decreased to
the control level on the ninth day.
After the injection of some individual probiotic cultures
and some of their compositions into the infected mice, an
increase in the level of indicators controlling the number of
CD3? and/or CD4? cells (third day) in the spleen was
observed, while the level of CD8? cells was normal, and
an increase in the number of CD19? cells was observed in
different periods. It was found (Table 3) that the number of
CD3? and CD4? cells on the third day in the spleens of
infected mice increased under the inﬂuence of Lact. casei
IMV B-7280 compared with the infected mice that did not
receive the probiotic cultures. Following injection of
B. longum VK1 into the infected mice, on the third day,
only a tendency to increase in the number of CD3? cells
and a probable increase in the number of CD4? cells was
observed. The number of CD3? and CD4? cells was
smaller on the third day in the spleen of infected mice who
received either Lact. acidophilus IMV B-7279 or B. biﬁ-
dum VK2 separately than in the control. After the injection
of Lact. acidophilus IMV B-7279 into the infected mice,
the number of CD3? cells on the ﬁrst day appeared to be
lower than in the control. However, it should be noted that
after the injection of all these probiotic cultures into the
infected mice, a separate increase in the CD4/CD8 index
was detected on the third day compared with the infected
mice who did not receive probiotic cultures. This may be
due to an increase in the number of CD4? cells under the
inﬂuence of Lact. casei IMV B-7280 or B. longum VK1, or
due to the reduction in the number of CD8? cells under the
inﬂuence of Lact. acidophilus IMV B-7279 or B. biﬁdum
Table 2 Numbers of
T-, B-lymphocytes in the
spleens of mice receiving
injections of Lact. casei IMV
B-7280, Lact. acidophilus IMV
B-7279, B. longum VK1,
or B. biﬁdum VK2 separately
Signiﬁcant differences with the
control is represented by
*( P\0.05) while differences
with the indicators of the
infected mice who did not
receive probiotic strains or their
compositions are represented by
• (P\0.05)
Groups of mice/time of
observation, day
Relative number of cells, % CD4/CD8,
nominal units
CD3? CD4? CD8? CD19?
Intact 61.9 ± 2.5 38.6 ± 1.3 26.3 ± 4.9 7.1 ± 0.5 1.5 ± 0.1
Infected
First day 63.8 ± 1.3 38.6 ± 0.4 22.8 ± 0.1 6.7 ± 0.1 1.7 ± 0.5
Third day 53.3 ± 0.7* 29.5 ± 0.5* 27.1 ± 0.5 10.5 ± 1.7 1.0 ± 0.1*
Sixth day 56.3 ± 3.2 37.5 ± 0.7 23.6 ± 2.3 15.3 ± 1.6* 1.6 ± 0.3
Ninth day 56.6 ± 8.5 36.9 ± 2.5 24.1 ± 2.2 9.6 ± 2.7 1.5 ± 0.2
Received Lact. acidophilus IMV B-7279
First day 53.3 ± 2.5* 34,0 ± 2.1 22.1 ± 5.3 11.3 ± 1.0* 1.6 ± 0.7
Third day 52.3 ± 1.3* 32.1 ± 1.2* 21.1 ± 1.9 10.4 ± 1.7 1.5 ± 0.1
•
Sixth day 56.4 ± 4.1 35.0 ± 1.4 23.5 ± 0.7 10.1 ± 1.1 1.5 ± 0.4
Ninth day 60.5 ± 2.0 40.1 ± 0.1 26.3 ± 0.2 9.9 ± 2.2 1.5 ± 0.2
Received Lact. casei IMV B-7280
First day 59.5 ± 3.8 35.0 ± 3.6 17.7 ± 4.5 8.7 ± 1.3 1.9 ± 0.4
Third day 58.0 ± 0.8
• 38.3 ± 0.5
• 25.7 ± 0.5 8.5 ± 1.9 1.5 ± 0.1
•
Sixth day 59.8 ± 3.6 39.2 ± 3.7 23,9 ± 0,3 7.2 ± 0.7 1.6 ± 0.5
Ninth day 59.3 ± 2.9 38.2 ± 3.3 21.1 ± 4.0 8.3 ± 2.2 1.8 ± 0.4
Received B. longum VK1
First day 55.0 ± 1.9 33.0 ± 5.9 21.4 ± 3.0 12.1 ± 0,9* 1.5 ± 0.2
Third day 56.8 ± 2.9 38.9 ± 1.1
• 17.0 ± 4.1 5.0 ± 0.9 2.3 ± 0.2*
•
Sixth day 55.9 ± 3.7 32.8 ± 3.0 23.4 ±3.5 6.7 ± 1.0 1.4 ± 0.4
Ninth day 62.9 ± 5.9 41.3 ± 3.8 26.0 ± 1.0 6.0 ± 2.9 1.6 ± 0.2
Received B. biﬁdum VK2
First day 61.9 ± 3.9 40.5 ± 1.5 21.0 ± 2.2 11.2 ± 1.7* 1.9 ± 0.1
Third day 54.1 ± 1.8* 32.6 ± 0.9* 22.3 ± 1.9 6.8 ± 3.9 1.5 ± 0.1
•
Sixth day 58.8 ± 2.2 40.3 ± 5.0 21.5 ± 4.0 10.4 ± 1.5 1.9 ± 0.4
Ninth day 55.0 ± 6.1 33.2 ± 4.1 21.4 ± 3.9 13.3 ± 1.1* 1.6 ± 0.3
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123VK2. At other times of observation following the injection
of these probiotic cultures separately into the infected
mice, the number of CD3?, CD4?, and CD8? cells and
the CD4/CD8 index were preserved on the level of control.
It was shown that in the spleen of infected mice, the
number of CD19? cells also increased on the ﬁrst day after
the injection of Lact. acidophilus IMV B-7279 or B. lon-
gum VK1 separately, and on the ﬁrst and ninth days after
the injection of B. biﬁdum VK2. The number of CD19?
cells did not change in the spleens of infected mice that
received Lact. casei IMV B-7280.
An increase in the number of CD3? and CD4? cells to
the control level was observed on the third day in the
spleens of infected mice under the inﬂuence of the fol-
lowing compositions of two probiotic cultures (Table 3):
Lact. casei IMV B-7280—B. biﬁdum VK2, Lact. casei
IMV B-7280—B. longum VK1 or Lact. acidophilus IMV
B-7279—B. biﬁdum VK2. Injection of the Lact. acidoph-
ilus IMV B-7279—B. longum VK1 or Lact. acidophilus
IMV B-7279—Lact. casei IMV B-7280 composition sep-
arately into the infected mice on the third day did not cause
the increase in the number of CD3? and CD4? cells; in
the spleens of infected mice injected with the Lact. aci-
dophilus IMV B-7279—Lact. casei IMV B-7280 compo-
sition, the number of these cells also appeared to be low on
the ﬁrst day compared with both the control and the
infected mice that did not receive the composition of
probiotic cultures. The CD4/CD8 index rose on the third
day following the injection of the Lact. casei IMV
B-7280—B. biﬁdum VK2 composition into the infected
mice (due to an increase in the number of CD4? cells) and
also on the sixth and ninth days (due to the tendency to
Table 3 Numbers
of T-, B-lymphocytes in the
spleens of mice who received
compositions of two strains of
Lact. casei IMV B-7280,
Lact. acidophilus IMV B-7279,
B. longum VK1, or B. biﬁdum
VK2
Signiﬁcant differences with the
control is represented by
*( P\0.05), while differences
with the indicators of the
infected mice who did not
receive probiotic strains or their
compositions are represented by
• (P\0.05)
Groups of mice/time of
observation, day
Relative number of cells, % CD4/CD8,
nominal units
CD3? CD4? CD8? CD19?
Intact 61.9 ± 2.5 38.6 ± 1.3 26.3 ± 4.9 7.1 ± 0.5 1.5 ± 0.1
Infected
First day 63.8 ± 1.3 38.6 ± 0.4 22.8 ± 0.1 6.7 ± 0.1 1.7 ± 0.4
Third day 53.3 ± 0.7* 29.5 ± 0.5* 27.1 ± 0.5 10.5 ± 1.7 1.0 ± 0.1
Sixth day 56.3 ± 3.2 37.5 ± 0.7 23.6 ± 2.3 15.3 ± 1.6* 1.6 ± 0.5
Ninth day 56.6 ± 2.5 36.9 ±.,5 24.1 ± 2.2 9.6 ± 2.7 1.5 ± 0.2
Received Lact. casei IMV B-7280—B. biﬁdum VK2
First day 61.9 ± 0.9 40.2 ± 4.5 21.7 ± 3.5 7.4 ± 0.5 1.9 ± 0.4
Third day 61.6 ± 1.0
• 38.2 ± 1.1
• 23.0 ± 2.4 9.1 ± 1.5 1.7 ± 0.1
•
Sixth day 55.1 ± 9.5 34.0 ± 2.9 16.9 ± 5.1 8.0 ± 0.5 2.0 ± 0.1
•*
Ninth day 55.0 ± 5.1 38.2 ± 3.8 16.4 ± 3.4 6.0 ± 3.4 2.3 ± 0.2
•*
Received Lact. casei IMV B-7280—B. longum VK1
First day 62.2 ± 3.0 32.4 ± 2.6 19.2 ± 2.9 10.1 ± 5.1 1.7 ± 0.3
Third day 59.3 ± 1.5
• 36.7 ± 1.0
• 19.6 ± 6.1 12.0 ± 1.0* 1.9 ± 0.1
•
Sixth day 57.0 ± 1.3 37.0 ± 2.8 24.6 ± 3.1 9.4 ± 2.1 1.5 ± 0.4
Ninth day 55.0 ± 2.9 37.1 ± 3.0 22.5 ± 7.5 12.4 ± 1.5* 1.6 ± 0.5
Received Lact. acidophilus IMV B-7279—B. biﬁdum VK2
First day 55.1 ± 4.1 34.9 ± 4.2 21.6 ± 4.0 9.0 ± 4.1 1.6 ± 0.2
Third day 59.2 ± 0.5
• 37.6 ± 3.1
• 23.4 ± 3.1 10.1 ± 6.2 1.6 ± 0.1
•
Sixth day 64.6 ± 2.5 41.9 ± 4.0 24.4 ± 4.2 14.6 ± 1.0* 1.7 ± 0.3
Ninth day 61.3 ± 2.0 38.0 ± 2.4 26.4 ± 3.2 10.6 ± 4.6 1.4 ± 0.1
Received Lact. acidophilus IMV B-7279—B. longum VK1
First day 57.1 ± 4.1 39.0 ± 4.9 24.1 ± 5.1 13.7 ± 3.5* 1.6 ± 0.2
Third day 51.9 ± 1.5* 30.4 ± 1.2* 22.2 ± 3.1 6.3 ± 2.9 1.4 ± 0.1
Sixth day 56.5 ± 4.1 35.0 ± 3.5 20.8 ± 7.2 10.4 ± 2.2 1.6 ± 0.3
Ninth day 57.0 ± 3.0 36.3 ± 5.6 20.4 ± 4.1 9.1 ± 1.5 1.8 ± 0.5
Received Lact. acidophilus IMV B-7279—Lact. casei IMV B-7280
First day 50.1 ± 1.5* 31.8 ± 2.1* 18.6 ± 5.1 9.9 ± 2.0 1.7 ± 0.1
Third day 53.0 ± 2.1* 31.0 ± 2.0* 18.0 ± 4.6 11.3 ± 2.1* 1.7 ± 0.1
•
Sixth day 60.5 ± 3.5 35.7 ± 3.1 24.0 ± 3.5 7.5 ± 1.5 1.5 ± 0.3
Ninth day 61.3 ± 2.0 38.0 ± 2.7 26.4 ± 1.5 10.6 ± 2.0 1.4 ± 0.2
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123reduction in the number of CD8? cells). After Lact. casei
IMV B-7280—B. longum VK1 or Lact. acidophilus IMV
B-7279—B. biﬁdum VK2 injection, the CD4/CD8 index
rose only on the third day (due to increase in the number of
CD4? cells). Under the inﬂuence of the Lact. acidophilus
IMV B-7279—B. longum VK1 composition, the tendency
of the CD4/CD8 index to increase on the third day was
noted. However, after the injection of the Lact. acidophilus
IMV B-7279—Lact. casei IMV B-7280 composition into
the infected mice, this indicator also increased on the third
day (probably due to the tendency of the number of CD8?
cells to decrease). The number of CD19? cells, compared
with the indicators of control (intact mice), did not change
under the inﬂuence of the Lact. casei IMV B-7280—
B. biﬁdum VK2 composition, but did increase after the
injection of the following compositions into the infected
mice: Lact. casei IMV B-7280—B. longum VK1 (on the
third and ninth days), Lact. acidophilus IMV B-7279—
B. biﬁdum VK2 (on the sixth day), Lact. acidophilus IMV
B-7279—B. longum VK1 (on the ﬁrst day), Lact. aci-
dophilus IMV B-7279—Lact. casei IMV B-7280 (on the
third day) (Table 3). The number of CD19?, CD3?,
CD4?, and CD8? cells, and the CD4/CD8 index were
preserved at the level of control after the injection of the
compositions of two strains of probiotic bacteria into the
infected mice at other times of observation.
The number of CD3? and CD4? cells in the spleens of
infected mice increased up to the level of the control on the
third day under the inﬂuence of the following compositions
of three or four strains (Table 4): Lact. casei IMV
B-7280—B. longum VK1—Lact. acidophilus IMV
B-7279, Lact. acidophilus IMV B-7279—B. longum
VK1—B. biﬁdum VK2 or Lact. casei IMV B-7280—
B. biﬁdum VK2—B. longum VK1—Lact. acidophilus IMV
B-7279. After the injection of the Lact. casei IMV
B-7280—B. longum VK1—B. biﬁdum VK2 or Lact. casei
IMV B-7280—B. biﬁdum VK2—Lact. acidophilus IMV
B-7279 compositions, the number of CD4? cells rose up
on the third day compared with the indicators for the
infected mice who did not receive these compositions,
although the number of CD3? cells remained low com-
pared to the control indicators. On the third day, an
increase in the CD4/CD8 index was observed due to an
increase in the number of CD4? cells after the injection of
the following compositions separately into the infected
mice compared with the infected mice who did not receive
the probiotic bacteria: Lact. casei IMV B-7280—B. longum
VK1—B. biﬁdum VK2, Lact. casei IMV B-7280—B. lon-
gum VK1—Lact. acidophilus IMV B-7279, Lact. casei
IMV B-7280—B. biﬁdum VK2—Lact acidophilus IMV
B-7279 or Lact. casei IMV B-7280—B. biﬁdum VK2—
B. longum VK1—Lact. acidophilus IMV B-7279. After the
injection of the Lact. casei IMV B-7280—B. longum
VK1—B. biﬁdum VK2 composition into the infected mice,
this indicator also increased on the ﬁrst day. Only on the
third day, a tendency of the CD4/CD8 index to increase
was detected under the inﬂuence of the all studied groups,
but for the Lact. acidophilus—B. longum VK1—B. biﬁdum
VK2 composition, this indicator rose on the ﬁrst day. It was
shown that the number of CD19? cells (Table 4) increased
after the injection of the following compositions of strains
into the infected mice: Lact. casei IMV B-7280—B. lon-
gum VK1—B. biﬁdum VK2 (on the ninth day), Lact. casei
IMV B-7280—B. biﬁdum VK2—Lact. acidophilus IMV
B-7279 (on the third day), Lact. casei IMV B-7280—
B. longum VK1—Lact. acidophilus IMV B-7279 (on the
ﬁrst, third, and sixth days) or Lact. casei IMV B-7280—
B. biﬁdum VK2—B. longum VK1—Lact. acidophilus IMV
B-7279 (on the ﬁrst, third, and sixth days) (Table 4). After
the injection of the Lact. acidophilus IMV B-7279—
B. longum VK1—B. biﬁdum VK2 composition into the
infected mice, the number of CD19? cells did not change
compared to the control indicators. At other times of
observation, after the injection of compositions of three or
four probiotic bacteria into the infected mice, the number
of CD19?, CD3?, CD4?, and CD8? cells, and the CD4/
CD8 index were preserved at the level of the control
indicators.
Thus, Lact. casei IMD-7280 alone, as well as most
compositions of strains of lactobacilli and biﬁdobacteria
(except for the Lact. acidophilus IMV B-7279—B. lon-
gum VK1 and Lact. acidophilus IMV B-7279—Lact.
casei IMV B-7280 compositions) which were studied by
us, caused a normalization of cellular immunity indica-
tors: On the third day, the number of CD3? and/or CD4?
cells increased in the spleens of the infected mice com-
pared with those from infected mice that did not receive
probiotic cultures or their compositions. At the same time,
after the injection of Lact. acidophilus IMV B-7279 or
B. biﬁdum VK2 separately, or the composition of Lact.
acidophilus IMV B-7279—B. longum VK1 and Lact.
acidophilus IMV B-7279—Lact. casei IMV B-7280, into
the infected mice, normalization of the number of CD3?
and CD4? cells was not observed. However, these strains
of bacteria and their varied compositions did increase the
number of CD19? cells in various periods of observation.
An increase in the number of CD19? cells in the spleens
of the infected mice was also detected after the injection
of other strains of bacteria and compositions, except for
Lact. casei IMV B-7280 and the Lact. casei IMV
B-7280—B. biﬁdum VK2 and Lact. acidophilus IMV
B-7279—B. longum VK1—B. biﬁdum VK2 compositions.
At the same time, Lact. casei IMV B-7280 or the Lact.
casei IMV B-7280—B. biﬁdum VK2 or Lact. acidophilus
IMV B-7279—B. longum VK1—B. biﬁdum VK2 com-
positions did not inﬂuence the number of CD19? cells in
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indicators (intact mice).
Discussion
To determine the possibility of creating probiotic compo-
sitions based on strains of lactobacilli and biﬁdobacteria for
treatment of patients with dysbiosis and uncomplicated
infections of the urogenital tract, we performed a com-
prehensive study of the antibacterial and immune modu-
latory activities of the strains Lact. casei IMV B-7280,
Lact. acidophilus IMV B-7279, B. longum VK1, B. biﬁdum
VK2, and their various compositions. The model used was
experimental intravaginal infection of mice caused by
Staph. aureus [31], which is a frequent cause of dysbiosis
and of development of uncomplicated infections of the
human urogenital tract. It is considered that the use of
probiotics based on lactobacilli and biﬁdobacteria in the
treatment of such patients is an alternative therapy to
antibiotics and chemotherapy [8]. Studies on the antago-
nistic interactions between lactic acid bacteria and Staph.
aureus have been carried out in various laboratories
throughout the world over the past several decades [2]. It
has been repeatedly shown that many strains of lactobacilli
and biﬁdobacteria taken from the intestines and vagina
Table 4 Numbers of T-, B-lymphocytes in the spleens of mice who received compositions of three or four strains of Lact. casei IMV B-7280,
Lact. acidophilus IMV B-7279, B. longum VK1, or B. biﬁdum VK2
Groups of mice/time
of observation, day
Relative number of cells, % CD4/CD8,
arbitrary units
CD3? CD4? CD8? CD19?
Intact 61.9 ± 2.5 38.6 ± 1.3 26.3 ± 4.9 7.1 ± 0.5 1.5 ± 0.1
Infected
First day 63.8 ± 1.3 38.6 ± 0,4 22.8 ± 0,1 6.7 ± 0.1 1.7 ± 0.1
Third day 53.3 ± 0,7* 29.5 ± 0.5* 27.1 ± 0,5 10.5 ± 1.7 1.0 ± 0.1
Sixth day 56.3 ± 3.2 37.5 ± 0.7 23.6 ± 2,3 15.3 ± 1.6* 1.6 ± 0.1
Ninth day 56.6 ± 8.5 36.9 ± 2.5 24.1 ± 2,2 9.6 ± 2.7 1.5 ± 0.1
Received Lact. casei IMV B-7280—B. longum VK1—B. biﬁdum VK2
First day 51.2 ± 2.9 38.9 ± 1.7 19.6 ± 4.7 8.7 ± 0.9 2.0 ± 0.1
*
Third day 54.1 ± 1.3* 36.0 ± 0.5
• 21.5 ± 1.1 6.1 ± 1.7 1.7 ± 0.1
•
Sixth day 57.0 ± 2.7 40.8 ± 2.7 28.1 ± 2.0 10.3 ± 0.9 1.5 ± 0.1
Ninth day 56.0 ± 3.1 37.8 ± 1.0 28.6 ± 3.2 11.7 ± 1.1* 1.4 ± 0.1
Received Lact. casei IMV B-7280—B. longum VK1—Lact. acidophilus IMV B-7279
First day 55.1 ± 1.6 32.7 ± 2.1 23.1 ± 4.0 18.3 ± 1.7* 1.4 ± 0.1
Third day 58.0 ± 1.4
• 40.2 ± 1.0
• 26.4 ± 2.4 11.5 ± 0.9* 1.5 ± 0.1
•
Sixth day 57.0 ± 3.9 34.0 ± 2.7 22.9 ± 1.7 15.2 ± 1.7* 1.5 ± 0.1
Ninth day 58.9 ± 2.1 37.6 ± 3.3 26.5 ± 2.0 9.0 ± 2.1 1.4 ± 0.1
Received Lact. acidophilus IMV B-7279—B. longum VK1—B. biﬁdum VK2
First day 54.6 ± 3.2 38.3 ± 5.7 18.2 ± 3.1 6.3 ± 1.4 2.1 ± 0.1*
Third day 63.0 ± 0.7
• 36.0 ± 1.1
• 27.8 ± 4.0 10.0 ± 3.2 1.3 ± 0.1
Sixth day 55.0 ± 2.9 37.3 ± 3.4 23.4 ± 2.9 8.1 ± 2.7 1.6 ± 0.1
Ninth day 54.8 ± 3.1 35.5 ± 2.2 19.1 ± 3.7 8.2 ± 1.1 1.8 ± 0.1
Received Lact. casei IMV B-7280—B. biﬁdum VK2—Lact. acidophilus IMV B-7279
First day 57.3 ± 3.2 38.9 ± 3.0 23.8 ± 2.8 8.1 ± 2.3 1.6 ± 0.1
Third day 53.0 ± 2.6* 35.4 ± 0.9
• 18.8 ± 4.9 13.1 ± 1.1* 1.9 ± 0.1
•
Sixth day 60.3 ± 1.3 40.1 ± 2.4 26.2 ± 5.0 8.9 ± 2.4 1.5 ± 0.1
Ninth day 61.1 ± 3.5 41.7 ± 1.8 24.1 ± 2.9 7.7 ± 2.0 1.7 ± 0.1
Received Lact. casei IMV B-7280—B. biﬁdum VK2—B. longum VK1—Lact. acidophilus IMV B-7279
First day 55.5 ± 1.7 37.3 ± 4.0 24.4 ± 4.7 16.7 ± 3.8* 1.5 ± 0.1
Third day 59.4 ± 1.0
• 41.6 ± 1.3
• 24.3 ± 1.8 11.7 ± 0.9* 1.7 ± 0.1
•
Sixth day 56.1 ± 3.5 35.0 ± 2.7 23.6 ± 2.5 18.3 ± 1.1* 1.5 ± 0.1
Ninth day 58.9 ± 2.9 39.3 ± 3.1 27.2 ± 2.0 6.1 ± 0.9 1.4 ± 0.1
Signiﬁcant differences with the control is represented by * (P\0.05), while differences with the indicators of the infected mice who did not
receive probiotic strains or their compositions are represented by
• (P\0.05)
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123inhibit the growth of Staph. aureus in vitro. For example,
Lact. acidophilus EP317/402 [28], Lact. acidophilus
CL1285(
 ) and Lact. casei LBC80R [9]; Lact. plantarum
8P-A3, Lact. casei DN-114001, Lact. reuteri [4], B. lon-
gum Z4, B. biﬁdum U1[ 11], and some other strains of
Biﬁdobacterium [12] had antagonistic activity in vitro in
relation to Staph. aureus. On the mouse model of intrav-
aginal staphylococcosis, Lact. paracasei CRL 1289 pre-
vented vaginal colonization of a uropathogenic strain of
Staph. aureus, which was conﬁrmed by the reduction in
cell numbers, the normalization of inﬂammation, and the
cytomorphological structure of the vaginal mucous mem-
brane [35]. Lact. rhamnosus GR-1, Lact. fermentum RC-14
and Lact. crispatus CTV-05 also demonstrated their
effectiveness against agents of infectious diseases of the
urogenital tract both in vitro and on animal models [6, 17,
21, 24, 25]. The efﬁcacy and safety of Lact. rhamnosus
GR-1 and Lact. fermentum RC-14 as treatments were
proven in several clinical studies of intravaginal applica-
tion [23] and their consumption in milk [22]. At the same
time, the search for other strains of lactic acid bacteria that
are highly effective against staphylococci and could be
used to create probiotic drugs remains the issue of the day.
All of the probiotic bacterial strains tested in monoculture
showed signiﬁcant anti-staphylococcal activity on in vivo
models of experimental intravaginal infection of mice
induced by Staph. aureus 8325-4. However, their anti-
staphylococcal action in vitro and in vivo was different.
The in vitro antagonistic activity in relation to strains of
Staph. aureus 8325-4 can be assessed as follows: Lact.
acidophilus IMV B-7279[B. biﬁdum VK2[B. longum
VK1/Lact. casei IMV B-7280. Thus, in vivo B. biﬁdum
VK2 or Lact. casei IMV B-7280 showed the highest
individual antagonistic activity against Staph. aureus
8325-4. This may be explained by the fact that probiotic
bacteria can use different mechanisms of anti-staphylo-
coccal action in vitro and in vivo. Primarily, this is due to
their competitiveness with the pathogen [34, 35] and with
different levels of adhesion to epithelial cells. Indeed, Lact.
casei IMV B-7280, B. biﬁdum VK2, and B. longum VK1
have shown higher levels of adhesion to epithelial cells
than Lact. acidophilus IMV B-7279 (unpublished data).
The important anti-staphylococcal mechanisms of action of
lactobacilli and biﬁdobacteria in vivo are the production of
lactic acid, hydrogen peroxide, bacteriocins-like com-
pounds (antimicrobial peptides), and other biologically
active substances [1, 16].We have not studied these in
relation to Lact. casei IMV B-7280, Lact. acidophilus IMV
B-7279, B. longum VK1, and B. biﬁdum VK2, and they
will be the subject of future research.
Earlier, we demonstrated [29] that Lact. casei IMV
B-7280, Lact. acidophilus IMV B-7279, B. longum VK1
and B. biﬁdum VK2 are not antagonists of each other. This
allowed us to compose them in various compositions of
two, three, or four probiotic cultures. Our data indicate that
the studied probiotic cultures and their compositions have
an immunomodulatory effect in the mice infected with
Staphylococcus. We studied changes in the numbers of
T- and B-lymphocytes, and certain subpopulations of
T-lymphocytes in the spleen of the mice infected with
Staph. aureus 8325-4. Experimental models and studies on
patients have shown that the immunomodulatory mecha-
nism of action of many probiotic strains of lactobacilli and
biﬁdobacteria involves activation of cellular and humoral
immunity: the numbers of T- and B-lymphocytes increases,
as does their proliferative activity and production of a
series of imunoregulatory cytokines [3, 10, 13, 32, 33].
As we previously established on the model of intact
mice, Lact. casei IMV B-7280, Lact. acidophilus IMV
B-7279, B. longum VK1, and B. biﬁdum VK2 intensiﬁed
the production of endogenous interferon and activated
macrophages [27]. In this study, we showed that under the
inﬂuence of some strains, particularly Lact. casei IMV
B-7280 or B. longum VK1 alone, or several of the com-
positions of multiple probiotic cultures, the number of
CD3? and/or CD4? cells in the spleen of the infected
mice increased to the level of control on the third day,
compared with the infected mice who did not receive
probiotic cultures or their compositions. After injection of
the Lact. casei IMV B-7280—B. longum VK1—B. biﬁdum
VK2 composition (which demonstrated the best anti-
staphylococcal effect in vivo) into the mice infected with
staphylococcus, an increase in the number of CD4? cells
was observed in the spleen on the third day, while the
number of CD3? cells was the same as in the infected mice
who did not receive probiotic cultures or their composi-
tions. Moreover, the number of CD19? cells increased on
the ninth day in comparison with the control indicators
(intact mice). Combining Lact. casei IMV B-7280 and
B. longum VK1 in one composition is successful due to
normalization of the number of CD3? and CD4? cells
observed in the spleens of the infected mice. In terms of
their individual immune modulatory activities, the ﬁrst
strain induces the ‘‘late’’ interferon, while the second strain
induces the ‘‘early’’ interferon, as we previously showed
[18] on the model of intact mice. Thus, in our studies, there
was a correlation between the ability of strains of lacto-
bacilli and biﬁdobacteria or their compositions to inhibit
the growth of Staph. aureus in vivo and their various
immune modulatory properties. However, it should be
noted that the immunomodulatory action of Lact. casei
IMV B-7280 and B. longum VK1 separately, as well as
some compositions of other strains, was better than that of
the Lact. casei IMV B-7280—B. longum VK1—B. biﬁdum
VK2 composition having the highest anti-staphylococcal
action in vivo. The probiotic strains studied by us,
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mechanisms of inﬂuence on the development of the
immune response.
Thus, Lact. casei IMV B-7280, Lact. acidophilus IMV
B-7279, B. longum VK1, or B. biﬁdum VK2 can be used for
creating probiotic drugs effective against Staph. aureus and
having immunomodulatory effect. Lact. casei IMV
B-7280—B. longum VK1—B. biﬁdum VK2 appeared to be
the most promising composition. Before we can create a
commercial probiotic drug on the basis of these strains of
probiotic cultures for intravaginal use, further research
must be conducted. We plan to determine the strains’
inﬂuence on the growth of opportunistic ﬂora, especially
fungi of the Candida genus, as well as on the balance of the
production of pro- and anti-inﬂammatory cytokines,
namely the Th1- and Th2-types of cytokines. Our results
conﬁrm the validity of the requirements of the European
regulatory legislation in the ﬁeld of probiotics regarding
the need for comprehensive studies of biological activity of
both separate cultures and their combinations, which would
allow for the creation of effective probiotic drugs based on
monocultures of lactobacilli and/or biﬁdobacteria or their
various combinations.
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Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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